ClinConnect ClinConnect Logo
Search / Trial NCT06249984

Effects of Tobacco Cut and Nicotine Form on the Abuse Liability of Moist Snuff

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Jan 31, 2024

Trial Information

Current as of September 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how different types of moist snuff, a form of smokeless tobacco, affect how addictive it can be for users. Researchers are particularly interested in two factors: the cut of the tobacco (whether it's long or fine) and the amount of nicotine (the substance in tobacco that causes addiction) it contains. They want to understand how these characteristics influence how long people use moist snuff, how quickly it delivers nicotine to the body, and how much users enjoy it. The findings from this study could help support new laws aimed at making moist snuff less appealing and less addictive.

To take part in this trial, participants need to be adults who currently smoke or use smokeless tobacco, or teens aged 12-15 with parental consent. Eligible adults must have been using moist snuff regularly for at least six months and be willing to visit the clinic for five study sessions, where they’ll need to avoid using any tobacco or nicotine for 12 hours before the visits. It’s important to note that participants who are pregnant, breastfeeding, or have certain health conditions cannot join the study. If you meet these criteria or know someone who might, this trial could provide valuable insights into tobacco use and addiction.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • AIM 1 (Adults Tobacco User Adult Cohort \[TUAC\]): Exclusive adult smokers who smoked \>100 cigarettes or other combustible tobacco products in their lifetime and reported being current, every day, or some days/week smokers at time of enrollment
  • AIM 1 (TUAC): Exclusive SLT user reporting every day or some days use per week at time of enrollment
  • AIM 1 (TUAC): Or dual users who met criteria for both aims at time of enrollment who resided in participating Appalachian and urban counties
  • AIM 1 (Buckeye Teen Health Study \[BTHS\]): Male youth ages 12-15 in Appalachian and urban regions of Ohio with parental consent and participant assent given
  • AIM 2: As derived from Aim 1, commercially available SLT products used by TUAC and BTHS participants will be purchased from retailers in nearby Appalachian counties, as composition of SLT products can vary regionally
  • AIM 3: Adults aged 21 and older who reside in an Ohio Appalachian county and use SLT at least 6x/day for at least 6 months will be considered for this project
  • Daily use (at least 6 dips/day) of moist snuff for at least 6 months
  • Age 21 years or older
  • Reside in an Ohio Appalachian county or surrounding rural area
  • Willing to complete 5 study visits and provide informed consent study procedures, including abstaining from all tobacco, nicotine, and marijuana for 12 hours before clinic visits
  • Willing to abstain from nicotine and tobacco products 12-hours before study visit
  • Ability to read and speak English
  • Exclusion Criteria:
  • Pregnant, planning to become pregnant, or breastfeeding (will be verified with a urine pregnancy test at the first session visit)
  • Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
  • History of cardiac event or distress, including but not limited to uncontrolled high blood pressure, chest pain, and shortness of breath, within the past 3 months
  • Working with a cessation counselor, using cessation devices such as Chantix or Wellbutrin, or planning to quit within the next 3 months
  • Severe periodontal or oral lesions

About Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.

Locations

Columbus, Ohio, United States

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Brittney L Keller-Hamilton, PhD, MPH

Principal Investigator

Ohio State University Comprehensive Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported